Pfizer and biontech receive positive chmp opinion for omicron ba.4/ba.5-adapted bivalent covid-19 vaccine booster for children 5 through 11 years of age in european union

New york and mainz, germany, november 10, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced a booster dose of their omicron ba.4/ba.5-adapted bivalent covid-19 vaccine (comirnaty® original/omicron ba.4/ba.5 5/5-Μg) has been recommended for marketing authorization by the european medicines agency (ema) committee for medicinal products for human use (chmp) for children 5 through 11 years of age. the european commission will review the chmp recommendation and is expected to make a final decision soon.
BNTX Ratings Summary
BNTX Quant Ranking